|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-6-15
|
|
pubmed:abstractText |
To determine the maximum-tolerated dose (MTD) of doxorubicin when given in combination with cisplatin and the multidrug-resistance (MDR) modulator valspodar and the remission rate induced by this combination in patients with platinum- and anthracycline-resistant ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2983-93
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11408493-Adolescent,
pubmed-meshheading:11408493-Adult,
pubmed-meshheading:11408493-Aged,
pubmed-meshheading:11408493-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11408493-Carcinoma,
pubmed-meshheading:11408493-Cisplatin,
pubmed-meshheading:11408493-Cyclosporins,
pubmed-meshheading:11408493-Doxorubicin,
pubmed-meshheading:11408493-Drug Resistance, Multiple,
pubmed-meshheading:11408493-Drug Resistance, Neoplasm,
pubmed-meshheading:11408493-Female,
pubmed-meshheading:11408493-Humans,
pubmed-meshheading:11408493-Infusions, Intravenous,
pubmed-meshheading:11408493-Maximum Tolerated Dose,
pubmed-meshheading:11408493-Middle Aged,
pubmed-meshheading:11408493-Ovarian Neoplasms,
pubmed-meshheading:11408493-Salvage Therapy,
pubmed-meshheading:11408493-Survival Rate
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, Norwegian Radium Hospital, and Department of Clinical Pharmacology, National Hospital, Oslo, Norway. mark.baekelandt@klinmed.uio.no
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
